Baxter International Inc

Baxter reported second-quarter results that included 5% organic revenue growth and adjusted EPS of $0.56, which was well above FactSet consensus of $0.37 even when excluding a one-time tariff refund benefit of $0.11. Management increased its top- and bottom-line outlooks for 2026, too.

Why it matters: Continuing the nearly 60% climb since its recent low in March, Baxter shares rose over 15% in early trading July 30 on its improving organic growth trends across business lines and better-than-expected profitability. Organically, Baxter delivered 5% growth in its medical products and therapies business (legacy Baxter) and 4% growth in its healthcare systems and technologies segment (legacy Hill-Rom), which led the firm to boost its 2026 organic revenue growth outlook to 2% to 3% from flat to up 1% previously. The new management team appears focused on improving operating efficiencies, too, and is having some early success relative to expectations, which led to this quarter's outperformance that helped boost its 2026 adjusted EPS target by $0.10 to $1.95 to $2.15.

The bottom line: After incorporating mild adjustments to our near-term expectations related to this announcement, we are maintaining our fair value estimate on narrow-moat Baxter at $40 per share. Baxter shares appear to be moving from significantly undervalued territory to moderately undervalued on this report, which highlights management's early success with operational initiatives honed at previous employers known for executional excellence like Danaher. However, Baxter still faces high uncertainty, especially around care provider budgets that may get tested in the next few years, as new US regulations hurt insured volumes (primarily in 2026-27) and direct payments from states in Medicaid (2028). So, while we expect further improvement in profits, there may be volatility in Baxter's intermediate-term trajectory.

BLANK PAGE

We are keeping our fair value estimate at $40 per share.

Overall, after another tough year in 2025, we anticipate that Baxter's revenue could grow 3% compounded annually through 2030. That top-line expectation recognizes the challenges that Baxter faces during the next few years, including the voluntary shipment hold on its Novum infusion pump platform. Also, the company could face headwinds in its large capital equipment business, if hospital finances are challenged by a rising uninsured rate in the US, as the federal government reduces spending on the individual exchanges (starting in 2026) and Medicaid (starting in 2027).

We also expect adjusted EPS to grow 8% compounded annually through 2030, primarily on margin expansion under the new CEO, who aims to instill a continuous improvement culture into Baxter's operations. We also assume that free cash flows can reach levels roughly equivalent to adjusted net income, as the firm controls its working capital better in future. Additionally, share repurchases account for about 100 basis points of our adjusted EPS growth expectation through 2030, although they may remain muted in the near term.

We believe Baxter has dug a narrow moat around providing essential medical supplies and capital equipment to caregivers. It claims top-tier positions in most of its product lines and typically competes with a concentrated group of peers. Overall, we think it would be difficult for new firms to enter its targeted niches primarily because of the intangible assets surrounding its proprietary products and the switching costs associated with some of them, both of which form the basis of Baxter’s moat.

Legacy Baxter Offerings: Medical Products/Therapies and Pharmaceuticals (Narrow Moat)

Baxter’s legacy segments produce injectable therapies, such as IV solutions, nutritional products, and generic pharmaceuticals that are sold into the hospital setting and are sometimes administered through infusion systems, like ones that Baxter also sells. We believe these segments have narrow moats with intangible assets and customer switching costs surrounding them. For intangible assets, the company possesses numerous trademarks and patents around its various products, but we think the differentiated features and the company’s reputation surrounding the reliable production of these essential medical supplies tend to be the strongest part of its intangible asset moat source. Also, Baxter benefits from customer switching costs either in the form of razor/blade business models or contractual agreements for some of these offerings.

Infusion Pumps

In our opinion, the strongest moat in the legacy Baxter operations surrounds one of its smaller offerings—infusion pumps. Infusion pumps help hospital staff, primarily nurses, automatically administer medical therapies and often lead to recurring consumable sales of administrative sets for producers, like Baxter. Infusion pumps can be differentiated from an intangible asset perspective in this oligopoly of competitors, which includes Becton Dickinson and ICU Medical primarily in the United States and Fresenius SE and B. Braun primarily overseas. But most importantly, the pumps have relatively long lives (seven to nine years typically), which gives them a long period to enjoy recurring sales on administrative sets after the pumps are placed. Also, during replacement cycles, hospitals often stick with familiar technology to ensure smooth therapy administration and prevent workflow disruptions for their nursing and administrative staff, which helps companies like Baxter benefit from customer switching costs in this razor/blade business model.

Injectable Therapies

Baxter sells a variety of injectable therapies—including IV solutions, nutritional products, and generic pharmaceutical—where it typically faces limited competition due to significant barriers to entry around these businesses.

In IV solutions for example, we estimate that it takes nearly half a billion dollars and several years to build a manufacturing facility that would allow a new entrant to gain enough scale to enter. But that sort of investment would not even guarantee a new entrant could garner any business in this market because of the GPO contracting structure that locks out competition and guarantees volumes for incumbent suppliers like Baxter for at least the initial three-year period of each contracting period and typically much longer, given the ongoing advantages and trust that GPOs often display in incumbent suppliers. Overall, we think these GPO contracts help the company and other incumbent players keep new entrants at bay while also reinforcing their scale advantages relative to new entrants.

We see similar dynamics in Baxter’s nutritional and generic pharmaceutical businesses, although even more intangible assets are possible in these end markets on top of the tough regulatory and reputational requirements that are needed to make headway in any injectable therapy. Unique delivery systems and differentiated formulations, akin to Coke and Pepsi recipes in consumer goods, can help Baxter’s nutritional products stand out to hospital customers. Even in generic pharmaceuticals, Baxter primarily participates in markets with complex manufacturing and administration requirements. In both its inhaled anesthetics and injectable therapy franchises, Baxter typically faces competition from only a few competitors, primarily due to manufacturing complexity, which is much more favorable than oral generics. For example, Baxter excels in aseptic premix product manufacturing, which is required to keep some molecules stable and helps ensure safety when nurses administer those products. Offering ready-to-use injectables in the care setting can improve patient safety and reduce the time associated with administration tasks, which creates a valuable tool for caregivers on the front lines of care and helps Baxter generate some mix benefits even in these "generic" niches.

Healthcare Systems/Technologies (No Moat)

While the late-2021 Hillrom acquisition added some proprietary offerings, primarily with intangible assets, to Baxter’s portfolio, the price paid and subsequent reduction in demand for those products make us think that the deal destroyed some value for Baxter from a moat perspective. Also, those products, which now make up Baxter’s healthcare systems and technologies segment, probably were on the weak end of the narrow-moat spectrum at best, in our opinion, prior to Baxter’s acquisition of them. The current product portfolio of smart beds, OR equipment, and patient monitoring devices can be intangible asset-heavy. These offerings largely appear to lack the key moat source that pushes many medical technology companies into the narrow-moat category—customer switching costs—and we do not see a strong moat, if any, surrounding this business.

In the long run, Baxter should continue to grow at a decent clip, primarily around evolutionary innovation in all of the major business lines and moderate pricing or mix improvements.

Emerging markets are a prime source of growth for many of Baxter's products, including nutritional solutions.

The company continues to strive toward higher margins, which may help earnings grow faster than sales in the long run, especially if its new CEO introduces some of his former employer's (Danaher's) ways to continuously improve Baxter's operations.

Although Baxter's products are essential for medical care and patient health, GPO contract negotiations can limit pricing power and flexibility.

With the late 2021 Hillrom deal, Baxter's previous management team added uncertainty to its ROIC prospects and reduced its balance-sheet flexibility, a problem that still persists.

Baxter's reputation as a reliable supplier of injectable therapies and related market share fell after hurricanes struck manufacturing facilities in 2017 and 2024. The company needs to guard against further problems in this area to maintain customer confidence.